Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETC-1002 in Hypercholesterolemia
NCT01262638Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Dec 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bempedoic acid in hypercholesterolemia (8 arms), sponsored by Esperion Therapeutics. Primary endpoints: Low-Density Lipoprotein-Cholesterol at 12 weeks and Low-Density Lipoprotein-Cholesterol by Triglyceride Stratum at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01262638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262638.